muramylnac-ala-isogln-lys-tripeptide has been researched along with interleukin-8 in 1 studies
| Studies (muramylnac-ala-isogln-lys-tripeptide) | Trials (muramylnac-ala-isogln-lys-tripeptide) | Recent Studies (post-2010) (muramylnac-ala-isogln-lys-tripeptide) | Studies (interleukin-8) | Trials (interleukin-8) | Recent Studies (post-2010) (interleukin-8) |
|---|---|---|---|---|---|
| 50 | 4 | 1 | 23,523 | 1,167 | 9,990 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghosh, S; Hervé, M; Hunt, KA; Playford, RJ; van Heel, DA | 1 |
1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and interleukin-8
| Article | Year |
|---|---|
Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Genotype; Humans; Interleukin-1; Interleukin-8; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptidoglycan; Tumor Necrosis Factor-alpha | 2006 |